Another notable valuation metric for GMED is its P/B ratio of 2.13. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus ...

Globus Medical, Inc. GMED recently completed its previously disclosed acquisition of Nevro Corp., a global medical device company that delivers comprehensive, life-changing solutions for the ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) on April 15 and set a price target of $101.00. Discover outperforming stocks and invest ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $88.00. The company’s shares closed last Friday ...

Globus Medical GMED has outperformed the market over the past 10 years by 1.4% on an annualized basis producing an average annual return of 11.03%. Currently, Globus Medical has a market ...

GMED opened at $73.67 on Friday. The stock has a market capitalization of $10.13 billion, a price-to-earnings ratio of 98.22, a PEG ratio of 1.61 and a beta of 1.19. The company has a fifty day ...